Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors

被引：0
|
作者：
Nakahara, Y. [1 ]
Himuro, H. [2 ]
Igarashi, Y. [2 ]
Kouro, T. [2 ]
Higashijima, N. [2 ]
Matsuo, N. [3 ]
Murakami, S.
Wei, F. [2 ]
Horaguchi, S. [2 ]
Tsuji, K. [2 ]
Mano, Y. [2 ]
Saito, H. [4 ]
Azuma, K. [3 ]
Naoki, K.
Sasada, T. [2 ]
机构：
[1] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[2] Kanagawa Canc Ctr Res Inst, Yokohama, Kanagawa, Japan
[3] Kurume Univ, Sch Med, Kurume, Fukuoka, Japan
[4] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Immune checkpoint inhibitors; Soluble PD-1; Soluble PD-L1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.01-11
引用
收藏
页码：S614 / S614
页数：1
相关论文
共 50 条
  • [21] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Wang, Dongxu
    Lin, Jianzhen
    Yang, Xu
    Long, Junyu
    Bai, Yi
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Seery, Samuel
    Zhao, Haitao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [22] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Dongxu Wang
    Jianzhen Lin
    Xu Yang
    Junyu Long
    Yi Bai
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Samuel Seery
    Haitao Zhao
    Journal of Hematology & Oncology, 12
  • [23] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
    Aden, Durre
    Zaheer, Samreen
    Sureka, Niti
    Trisal, Monal
    Chaurasia, Jai Kumar
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
  • [24] Covalent small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint
    Maslanka, A.
    Kitel, R.
    Konopka, J.
    Skalniak, L.
    FEBS OPEN BIO, 2024, 14 : 329 - 330
  • [25] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
    Caccese, Mario
    Indraccolo, Stefano
    Zagonel, Vittorina
    Lombardi, Giuseppe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134
  • [26] Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
    Ribatti, Domenico
    Cazzato, Gerardo
    Tamma, Roberto
    Annese, Tiziana
    Ingravallo, Giuseppe
    Specchia, Giorgina
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [27] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
    Mahoney, Kathleen M.
    Freeman, Gordon J.
    McDermott, David F.
    CLINICAL THERAPEUTICS, 2015, 37 (04) : 764 - 782
  • [28] Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc
    SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 314 - 331
  • [29] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
    Zhou, Yanting
    Li, Hongyan
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [30] Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer
    AmeliMojarad, Mandana
    AmeliMojarad, Melika
    Cui, Xiaonan
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
12345